Hypertension stands as a pervasive global health challenge, contributing significantly to mortality rates worldwide. Various factors, including lifestyle choices and dietary habits, contribute to the development of hypertension. In recent years, oxidative stress has garnered significant attention as a factor influencing hypertension risk, prompting a shift in research focus towards exploring it as a potential target for prevention and treatment. Antioxidants found in our diet, such as vitamins C, E and carotenoids exhibit the ability to neutralize reactive oxygen species, thereby mitigating oxidative stress. In addition, Vitamin A has an antioxidant effect despite not being an antioxidant itself. Consequently, supplementation or increased intake of these antioxidants has been hypothesized to potentially lower blood pressure levels and aid in the management of hypertension, thereby potentially prolonging life expectancy. Research findings regarding this effect have been diverse. This paper examines the existing literature demonstrating favorable outcomes associated with antioxidant supplementation.

Cardiovascular diseases stand as the predominant global cause of mortality, exerting a profound impact on both life expectancy and its quality. Given their immense public health burden, extensive efforts have been dedicated to comprehending the underlying mechanisms and developing strategies for prevention and treatment. Selenium, a crucial participant in redox reactions, emerges as a notable factor in maintaining myocardial cell homeostasis and influencing the progression of cardiovascular disorders. Some disorders, such as Keshan disease, are directly linked with its environmental deficiency. Nevertheless, the precise extent of its impact on the cardiovascular system remains unclear, marked by contradictory findings in the existing literature. High selenium levels have been associated with an increased risk of developing hypertension, while lower concentrations have been linked to heart failure and atrial fibrillation. Although some trials have shown its potential effectiveness in specific groups of patients, large cohort supplementation attempts have generally yielded unsatisfactory outcomes. Consequently, there persists a significant need for further research aimed at delineating specific patient cohorts and groups of diseases that would benefit from selenium supplementation.

Crohn’s disease (CD) is a chronic inflammatory condition of the digestive tract, driven by an imbalance in immune system regulation, where proinflammatory interleukin-23 (IL-23) plays an essential role. Selective new IL-23 inhibitors, including risankizumab, guselkumab, and mirikizumab, block the IL-23p19 subunit to inhibit the Il-23 action and alleviate inflammation in CD. This review explores the effectiveness, safety, and therapeutic potential of anti-IL-23 treatment in CD management. Risankizumab, guselkumab, and mirikizumab demonstrated considerable effectiveness in inducing clinical remission and promoting endoscopic healing in patients with moderately to severely active CD, including those refractory to anti-TNF therapies. Risankizumab showed favorable results in pivotal trials like ADVANCE, MOTIVATE, and FORTIFY, achieving remission rates of up to 45% and sustained inflammatory biomarkers normalization. Guselkumab and mirikizumab similarly demonstrated substantial efficacy in the induction and maintenance phases, with promising long-term results. The safety profiles of IL-23 inhibitors were favorable, with low rates of serious adverse events, including infections and malignancies. Selective new IL-23 inhibitors represent a targeted and effective therapeutic class for moderately to severely active CD, offering high clinical and endoscopic remission rates, and favorable safety outcomes. Continued research, particularly on long-term efficacy and the selection of patients based on inflammatory biomarkers, will help optimize their role in personalized treatment strategies for refractory CD.

Systemic sclerosis (SSc) represents a rare and intricate autoimmune connective tissue disease, the pathophysiology of which has not been fully understood. Its key features include progressive fibrosis of the skin and internal organs, vasculopathy and aberrant immune activation. While various anti-nuclear antibodies can serve as biomarkers for the classification and prognosis of SSc, their direct role in organ dysfunction remains unclear. Anti-Th/To antibodies are present in approximately 5% of SSc patients, and are particularly prevalent among those with the limited subtype of the disease. Although the presence of these autoantibodies is associated with a mild course of the disease, there is a strong connection between them and severe clinical manifestations of SSc, including interstitial lung disease, pulmonary arterial hypertension and gastrointestinal involvement. Also, the additional clinical correlations, particularly with malignancies, need further research. Moreover, the disease’s course seems to be influenced by antibodies, specific serum cytokines and TLR signaling pathways. Understanding the relationships between presence of anti-Th/To, its molecular aspects and response to treatment options is crucial for the development of novel, personalized therapeutic techniques and should undergo profound analysis in future studies.

Background: Ulcerative Colitis and Crohn’s Disease are the most common forms of inflammatory bowel disease (IBD), with increasing prevalence both globally and in Poland. Many aspects of a patients’ everyday functioning and treatment remain underexplored. Methods: This study recruited adult patients with IBD hospitalized in the Department of Digestive Tract Diseases of the Medical University of Lodz, Poland. The data were collected between June and July 2025 using an author-developed questionnaire assessing patients’ opinions on therapy, their expectations, and overall life satisfaction. Results: A total of 87 patients with IBD were included in the analysis. Overall, 59 patients (67.82%) reported strong satisfaction with their current treatment, indicating a generally positive perception of disease management. Higher treatment satisfaction was associated with patients’ perception that their preferences were respected by the gastroenterologist. Further analysis revealed significant associations between different types of treatment, disease activity, and patient-reported outcomes. Those patients who were treated with biological agents more frequently reported complete satisfaction with the treatment (41/52 vs. 18/35; p = 0.014), low-to-moderate disease activity (42/52 vs. 19/35; p = 0.016), and fewer limitations in their social lives (16/52 vs. 20/35; p = 0.026) compared to the remaining group. Furthermore, the study demonstrated that those patients who reported remission were less likely to have their physical activity limited (27/55 vs. 27/32; p = 0.002). There were significantly more patients under 50 years of age than older patients getting biological therapy (48/74 vs. 4/13; p = 0.045). Additionally, women in the studied group had a higher rate of IBD-related surgical interventions compared to men (15/36 vs. 9/51; p = 0.026). Despite the high overall satisfaction with treatment and physician communication, 20 patients (22.99%) admitted to taking additional, non-prescribed medication or dietary supplements. Similarly, 21 (24.14%) patients modified treatment regimens by discontinuing the medication intake or changing the prescribed dose. Furthermore, 57 patients (65.52%) reported that they feared the possibility of surgical intervention. Nonetheless, the majority of patients who underwent surgical treatment (22/24; 91.67%) were satisfied with the results. Reported rates of undergoing regular colorectal cancer screening were also unsatisfactory—4/37 (10.81%) patients with disease duration > 8 years, suggesting inadequate awareness. Conclusions: Biological treatment can positively impact multiple aspects of patients’ lives by lowering the disease’s activity. Gastroenterologists should spend more time discussing patients’ preferences and concerns, as well as explaining the colorectal cancer screening rules.

Statins, or HMG-CoA reductase inhibitors, represent one of the most extensively researched and frequently prescribed pharmacological agents, primarily utilized to reduce cardiovascular risk through the modulation of serum cholesterol levels. Although their efficacy in reducing global mortality and cardiovascular events is well-established, genetic variability persists among different populations which may predispose patients to dose-related adverse effects and reduced efficancy of statin therapy. This heterogeneity has driven a shift in the scientific landscape toward exploring common genetic polymorphisms within the genes encoding genes involved in pharmacodynamic pathways. This review aims to provide a comprehensive analysis of clinically significant polymorphisms within the pharmacodynamic pathways of statins. Methods: A systematic literature review was conducted in accordance with PRISMA guidelines. Databases including PubMed, Embase, and the Cochrane Library were searched for peer-reviewed publications from 2021 to 2025. Following a rigorous selection process based on Evidence-Based Medicine (EBM) criteria. Conclusions: Despite rapid progress in the field of pharmacogenomics, the role of genetic polymorphisms among genes involved in pharmacodynamic pathways of statin therapy still requires more research in order to establish robust evidence of their role in the overall lipid-lowering efficacy of statins.